All In Biotech

Drug Trial Radar · NCT05039177

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)

Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

101

Actual

Start

Sep 20, 2021

Primary completion

Aug 15, 2025

Study completion Jan 26, 2026

Sponsor

Lead sponsor
Erasca, Inc.Industry
Sponsor type
Industry
First posted
Sep 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.

Conditions

  • Metastatic Colorectal Cancer
  • Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • ERAS-007Drug

    Administered orally

  • EncorafenibDrug

    Administered orally

  • CetuximabDrug

    Administered via intravenous infusion

  • PalbociclibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 29
  2. Maximum Tolerated Dose (MTD)Time frame: Study Day 1 up to Day 29
  3. Recommended Dose (RD)Time frame: Study Day 1 up to Day 29
  4. Adverse EventsTime frame: Assessed up to 24 months from time of first dose

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)

    Birmingham, Alabama

  • City of Hope

    Duarte, California

  • University of California Irvine College of Medicine

    Orange, California

  • UCSF Mount Zion Medical Ctr

    San Francisco, California

  • The Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Cancer Institute

    Detroit, Michigan

  • Washington University (Siteman Cancer Center)

    St Louis, Missouri

  • Duke Cancer Institute

    Durham, North Carolina

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Sarah Cannon Research Institute (Tennessee Oncology)

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • University of Washington - Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.